Anti-EGR2 / Early growth response protein 2

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. EGR2 antibody detects Early growth response protein 2 (also known as Krox-20), a zinc finger transcription factor that governs peripheral nerve myelination, hindbrain segmentation, and immune regulation. Encoded by the EGR2 gene on chromosome 10q21.3, this transcription factor belongs to the early growth response family of immediate-early genes activated by mitogenic and stress stimuli. EGR2 contains three C2H2-type zinc finger motifs that bind GC-rich DNA sequences to regulate genes controlling differentiation and growth arrest. It is essential for Schwann cell maturation and myelin gene expression in the peripheral nervous system.During development, EGR2 plays a critical role in establishing segmental identity within the hindbrain by defining rhombomere boundaries and activating patterning genes. In Schwann cells, EGR2 drives transcription of myelin structural proteins including MPZ, PMP22, and MBP, ensuring proper myelin sheath formation and maintenance. Mutations in EGR2 cause hereditary neuropathies such as Charcot-Marie-Tooth disease type 1D and Dejerine-Sottas syndrome, underscoring its indispensable function in myelination. The protein also participates in T-cell anergy and macrophage activation by regulating cytokine gene expression.The EGR2 antibody is widely used in neurobiology, developmental biology, and immunology to detect EGR2 protein expression and localization. Western blot analysis typically shows a 50 kilodalton band, while immunohistochemistry reveals strong nuclear staining in Schwann cells and developing neurons. Expression of EGR2 is inducible by growth factors, nerve injury, and mechanical stress, making it a sensitive marker for differentiation and regeneration. In the immune system, EGR2 acts as a transcriptional repressor in T cells to maintain peripheral tolerance by suppressing activation genes.Beyond its physiological roles, EGR2 has been implicated in tumor biology and inflammatory disease. Altered EGR2 signaling can disrupt differentiation programs and contribute to leukemogenesis or autoimmune disorders. In cancer models, EGR2 functions context-dependently as either a tumor suppressor or pro-survival factor, depending on cellular environment. The EGR2 antibody allows researchers to explore these regulatory networks, providing a means to monitor transcriptional changes during neural development and immune modulation. NSJ Bioreagents provides this antibody validated for its applications, ensuring consistent and specific detection across experimental systems.